A case of ruptured hepatic metastases during pembrolizumab administration for cutaneous malignant melanoma

An Bras Dermatol. 2024 May-Jun;99(3):450-451. doi: 10.1016/j.abd.2022.10.015. Epub 2024 Feb 1.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Antibodies, Monoclonal, Humanized* / therapeutic use
  • Antineoplastic Agents, Immunological* / adverse effects
  • Fatal Outcome
  • Female
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / secondary
  • Male
  • Melanoma* / drug therapy
  • Melanoma* / pathology
  • Melanoma* / secondary
  • Melanoma, Cutaneous Malignant
  • Middle Aged
  • Rupture, Spontaneous / chemically induced
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / pathology

Substances

  • pembrolizumab
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents, Immunological